Product List     API & Intermediate     

Pharmaceutical Intermediates

Find
3742
related chemicals for you
CAS:136470-78-5
Molecular Formula:C14H18N6O
(1S,4R)-4-[2-Amino-6-(Cyclopropylamino)-9H-Purin-9-Yl]-2-Cyclopentene-1-Methanol; Abacavir; Ziagen; Abacavir Sulfate; Unii-Wr2Tip26Vs; Abacavir (See A105000)
Brief Introduction
Abacavir API is often used as an AIDS adjuvant.
CAS:137-58-6
Molecular Formula:C14H22N2O
2-(Diethylamino)-N-(2,6-Dimethylphenyl)-Acetamide; 2-Diethylaminoacet-2,6-Xylidide; A-Diethylamino-2,6-Acetoxylidide; N1-(2,6-Dimethylphenyl)-N2,N2-Diethylglycinamide
Brief Introduction
The product is an amide local anesthetic. It is widely used in surface anesthesia, infiltration anesthesia, conduction anesthesia and epidural anesthesia.
CAS:13811-71-7
Molecular Formula:C8H14O6
(2S,3S)-Diethyl 2,3-Dihydroxysuccinate; Butanedioic Acid, 2,3-Dihydroxy-, Diethyl Ester, [S-(R*,R*)]-; D-(-)-Tartaric Acid Diethyl Ester; Diethyl-D-Tartrate
Brief Introduction
Diethyl (2S,3S)-2,3-dihydroxybutanedioate is mainly used in the synthesis of chiral drugs, chiral intermediates and asymmetric catalysis. It is also used in food and animal feed.
CAS:138526-69-9
Molecular Formula:C6H2BrF3
1,2,3-Trifluoro-5-Bromobenzene; 1-Bromo-3,4,5-Triflurobenzene; 3,4,5-Trifluorobromobenzene; 5-Bromo-1,2,3-Trifluorobenzene; 1-Bromo-3,4,5-Trifluorobenzene; 1-Brom-3,4,5-Trifluorbenzol; 3,4,5-Ttrifluorobromobenzene; 5-Trifluorobromobenzene; 3,4,5-Trifluoro-1-Bromobenzene; 1-Bromo-3,4,5-Trifluoribenzene; Benzene, 5-Bromo-1,2,3-Trifluoro-; 1-Bromo-3, 4, 5-Trifluorobenzene
Brief Introduction
This product is mainly used as pharmaceutical intermediates.
CAS:14080-23-0
Molecular Formula:C5H3N3
2-Cynopyrimidine; 2-Cpy; Pyrimidin-2-Carbonitrile; 2Cpm; 2-Pyrimidinecarbonitrile; 2-Pyrimidinenitrile; Pyrimidine-2-Carbonitrile; 2-Pyrimidinecarbonitrile (6Ci,7Ci,8Ci,9Ci)
Brief Introduction
2-Cyanopyrimidine is a key intermediate in the synthesis of bosentan. Bosentan is a kind of drug for the treatment of pulmonary hypertension, which is suitable for the treatment of patients with pulmonary hypertension (PAH) of who functional classification II-IV (who group 1), in order to improve the exercise ability of patients and reduce clinical deterioration. Studies supporting the effectiveness of this product mainly included patients with idiopathic or hereditary PAH (60%) of who functional classification II-IV, PAH associated with connective tissue disease (21%) and PAH associated with left to right shunt congenital heart disease (18%).
Inquiry ( 
10
 
/ 10
 )
Clear All
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >